<DOC>
	<DOC>NCT01922089</DOC>
	<brief_summary>The purpose of this study is to assess the safety and tolerability of initiating LCZ696 in heart failure patients with reduced ejection fraction (HF-rEF) using conservative (reaching target dose over 6 weeks) and condensed (reaching target dose over 3 weeks) up-titration regimens.</brief_summary>
	<brief_title>Safety and Tolerability of Initiating LCZ696 in Heart Failure Patients</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>LCZ 696</mesh_term>
	<criteria>Age ≥ 18 years; CHF with New York Heart Association class IIIV; left ventricular ejection fraction ≤ 35%; on beta blockers Potassium &gt; 5.2 mmol/l; estimated glomerular filtration rate &lt; 30 ml/min/1.73 m2; systolic blood pressure &lt;100 mmHg or &gt; 180 mmHg; history of intolerance to recommended target doses of angiotensin converting enzyme inhibitors or angiotensin receptor blockers Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Heart failure, reduced ejection fraction, LCZ696, titration, safety, tolerability</keyword>
</DOC>